Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rocket Pharmaceuticals (RCKT) Total Non-Current Liabilities (2016 - 2025)

Historic Total Non-Current Liabilities for Rocket Pharmaceuticals (RCKT) over the last 10 years, with Q3 2025 value amounting to $53.3 million.

  • Rocket Pharmaceuticals' Total Non-Current Liabilities fell 1508.88% to $53.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $53.3 million, marking a year-over-year decrease of 1508.88%. This contributed to the annual value of $63.3 million for FY2024, which is 1059.71% down from last year.
  • As of Q3 2025, Rocket Pharmaceuticals' Total Non-Current Liabilities stood at $53.3 million, which was down 1508.88% from $65.7 million recorded in Q2 2025.
  • In the past 5 years, Rocket Pharmaceuticals' Total Non-Current Liabilities ranged from a high of $96.4 million in Q1 2021 and a low of $42.2 million during Q4 2021
  • Over the past 5 years, Rocket Pharmaceuticals' median Total Non-Current Liabilities value was $56.0 million (recorded in 2024), while the average stood at $56.9 million.
  • Data for Rocket Pharmaceuticals' Total Non-Current Liabilities shows a peak YoY increase of 4100.34% (in 2022) and a maximum YoY decrease of 5593.23% (in 2022) over the last 5 years.
  • Quarter analysis of 5 years shows Rocket Pharmaceuticals' Total Non-Current Liabilities stood at $42.2 million in 2021, then skyrocketed by 41.0% to $59.5 million in 2022, then grew by 18.99% to $70.8 million in 2023, then dropped by 10.6% to $63.3 million in 2024, then dropped by 15.83% to $53.3 million in 2025.
  • Its Total Non-Current Liabilities stands at $53.3 million for Q3 2025, versus $65.7 million for Q2 2025 and $57.8 million for Q1 2025.